Finally, a Diagnostic Marker for Lewy Body Disease?
α-Synuclein seed amplification assays identify people with LBD. They may outperform clinical diagnosis, and hint that dementia with Lewy bodies might be overdiagnosed.
ALL NEWS
6548 RESULTS
Sort By:
- Most Recent
- Most Commented
Does One Copy of the Christchurch ApoE Variant Slow Alzheimer’s?
Twelve people heterozygous for this protective variant were still sharp seven years after their expected age of AD onset. One had fewer tangles than expected.
Organization of Aβ Plaques and Tau Tangles Illuminated in AD Brain
Plaques comprise different-sized fibrils and cell membrane components, while tangles have distinct fibril structures segregated into intra- and extracellular compartments.
Wanted: Fluid Biomarkers for CAA, ARIA
The ability to quickly detect cerebral amyloid angiopathy and ARIA would make amyloid immunotherapy safer, but research in this area is just beginning.
Is ARIA an Inflammatory Reaction to Vascular Amyloid?
Scientists at AAIC said ARIA-E resembles inflammation related to cerebral amyloid angiopathy. The prime suspect? The complement cascade.
Spying on α-Synuclein Inclusions: PET Tracers Inch Closer to Success
A crop of new PET tracers that bind α-synuclein aggregates shows promise in tissue samples and in animal models. Will they prove potent enough for brain imaging?
Cohort LEADS Toward Better Understanding of Sporadic Early Onset AD
First data from the Longitudinal Early-Onset Alzheimer’s Disease Study hints at what might cause this type of AD and how it unfolds.
Could Inhibiting a Liver Enzyme Ameliorate Alzheimer’s Pathology in the Brain?
In mice, curbing a hepatic hydrolase boosted protective epoxy fatty acids in the brain, which stimulated microglia to clear amyloid.
CSF MTBR-tau-243 Tracks Tangles, Plummets in Response to Antibody
In contrast to phospho-tau species that mirror amyloid, CSF MTBR-tau-243 reflects tau-PET. It fell upon treatment with an antibody against tau’s midsection.
Give BACE Inhibitors a Second Chance?
Between basic researchers and clinicians, momentum is growing to test BACE inhibition again. This time, at low doses.
Donanemab Data Anchors Upbeat AAIC
Alzheimer’s researchers got their first look at data from the positive Phase 3 trial. Many expect this antibody to become the third approved immunotherapy for AD.
Alzheimer's Association International Conference (AAIC)- 2023
Donanemab Data Anchors Upbeat AAIC Give BACE Inhibitors a Second Chance? CSF MTBR-tau-243 Tracks Tangles, Plummets in Response to Antibody Cohort LEADS Toward Better Understanding of Sporadic Early Onset AD Spying on α-Synuclein Inclusions: PET Tracers In
Proteomics Discerns Sporadic from Familial Alzheimer’s Disease
While each disease features distinct proteomes in the brain, cerebrospinal fluid, and blood, some proteins overlap. They are more dysregulated in familial than in sporadic AD.
Too Basic: APP β-CTF's YENTPY Motif Binds Proton Pump, Thwarts Lysosomes
In cells from people with Down’s syndrome, and in mouse models of DS and Alzheimer’s, excess β-CTF binds vacuolar ATPase, hobbling lysosomal acidification.
CRISPR Screens Net Tau Partners in Human Neurons, Brain
Two interference screens netted a thousand proteins that affect tau oligomerization. The affected pathways? Mitochondrial malfunction, and UFMylation.
Current Filters
No filters selected